Journal Logo

AMITRIPTYLINE STRENGTHENS THE EFFECTS OF BORTEZOMIB AND MELPHALAN TREATMENT IN MULTIPLE MYELOMA BY INHIBITING ACID SPHINGOMYELINASE

PS1369

Faict, S.1; Oudaert, I.1; De Veirman, K.1; Maes, K.1; Jacobs, L.1; De Bruyne, E.1; Swinnen, J.2; Schots, R.1; Fostier, K.1; Vandebroek, I.3; Vanderkerken, K.1; D'Auria, L.4; Menu, E.1

doi: 10.1097/01.HS9.0000563752.90821.23
Poster Session II: Myeloma and other monoclonal gammopathies - Biology & translational research
Free

1Hematology and Immunology, Vrije Universiteit Brussel, Brussels

2Oncology, KULeuven, Leuven

3Hematology, AZ Nikolaas, Sint-Niklaas

4Insitute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium

Back to Top | Article Outline

Background:

Malignant cells can adapt their lipid metabolism to attain higher rates of proliferation, and resist chemotherapy-induced apoptosis.

Back to Top | Article Outline

Aims:

In this study, we aimed to identify the changes in lipid metabolism in multiple myeloma (MM) patients, and to further investigate the role of this altered metabolism in vitro.

Back to Top | Article Outline

Methods:

We performed a lipidomics analysis to compare plasma from MM patients to healthy controls. Based on these results, lipid spike-in assays enabled us to evaluate effects on MM cell proliferation. Sphingomyelinase (SMase) content of MM cells and their exosomes was measured, before and after treatment with standard-of-care drugs, using an AmplexRed assay. We inhibited both neutral and acid SMase (ASM) in MM cells to evaluate effects on drug efficacy. Finally, we investigated whether MM exosomes rich in ASM are able to induce drug resistance in MM cells low in ASM.

Back to Top | Article Outline

Results:

Lipidomics analysis revealed that several ceramide species were significantly more present in MM patient plasma, while sphingomyelin seemed to be decreased. When adding ceramide in vitro to MM cells, we observed higher viability and proliferation. The increased ceramide/sphingomyelin ratio in plasma lead us to believe that the sphingomyelinase enzyme, which converts sphingomyelin into ceramide, was upregulated in MM cells. This was confirmed in BM samples, comparing CD138+ MM cells to the CD138- fraction. In the MM cell lines JJN3, OPM2, LP1 and U266, we observed an increased expression of acid and total SMase when treating these cells with melphalan or bortezomib for 24 h. Furthermore, we investigated whether MM exosomes were involved in the secretion and transfer of acid SMase. Interestingly, amitriptyline, an inhibitor of acid SMase, often prescribed in MM patients for neuropathic pain, increased the efficacy of both drugs in vitro, and also induced apoptosis in primary MM cells as a single agent.

Back to Top | Article Outline

Summary/Conclusion:

SMase is increased in primary MM cells and cell lines upon treatment with melphalan and bortezomib, while inhibiting this expression using amitriptyline leads to a higher efficacy of drug therapy.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.